2026年10月16日星期五
M
Panorama Universal
Notícias globais
[Comment] Establishing cardiovascular safety of the small-molecule GLP-1 receptor agonist orforglipron in type 2 diabetes— 柳叶刀 Lancet[Comment] Making every vial count: fractional dosing of yellow fever vaccine— 柳叶刀 Lancet[Comment] Shortening treatment to accelerate hepatitis C elimination— 柳叶刀 Lancet[Comment] Offline: In praise of astrologers, sorcerers, and magicians— 柳叶刀 Lancet[World Report] “You have to be willing to take risks”: the 2026 Nobel prizes— 柳叶刀 Lancet[World Report] Health in Brazil's election— 柳叶刀 Lancet[Perspectives] Shadows and interiority— 柳叶刀 Lancet[Perspectives] Beyond the battlefield: war and global health security— 柳叶刀 Lancet[Comment] Establishing cardiovascular safety of the small-molecule GLP-1 receptor agonist orforglipron in type 2 diabetes— 柳叶刀 Lancet[Comment] Making every vial count: fractional dosing of yellow fever vaccine— 柳叶刀 Lancet[Comment] Shortening treatment to accelerate hepatitis C elimination— 柳叶刀 Lancet[Comment] Offline: In praise of astrologers, sorcerers, and magicians— 柳叶刀 Lancet[World Report] “You have to be willing to take risks”: the 2026 Nobel prizes— 柳叶刀 Lancet[World Report] Health in Brazil's election— 柳叶刀 Lancet[Perspectives] Shadows and interiority— 柳叶刀 Lancet[Perspectives] Beyond the battlefield: war and global health security— 柳叶刀 Lancet

[Correspondence] Optimising standard of care in non-small-cell lung cancer trials – Authors’ reply

Fonte 柳叶刀 LancetAgora mesmo
Resumo do conteúdo

We thank Emma D A Wagener and Wouter H van Geffen for emphasising the importance of comparator selection. We agree that pembrolizumab plus platinum-based chemo…

Este site fornece apenas o título e o índice do resumo; o conteúdo completo e os direitos autorais pertencem ao publicador original. Clique no link do texto original para ler.

Ir para o texto original
Canal de origem
Saúde
Região de origem
Reino Unido
Idioma do texto original
English
Número do item
health-514fc802

Comments 0 comments

No comments yet. Be the first.

[Correspondence] Optimising standard of care in non-small-cell lung cancer trials – Authors’ reply · Panorama Universal